A Phase 1/2 Open-Label Dose-Escalation Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Brief description of study
If you have been diagnosed with advanced or metastatic solid tumors, you may qualify to participate in this study. The main goal of this phase 1/2 clinical trial is to evaluate the dafety, tolerability, and toxicities of the investigational drug, INCAGN01949 (an OX40 agonist monoclonal antibody). In addition, we would like to study blood samples to understand how much INCAGN01949 is in the blood over time, which is known as pharmacokinetic (PK) testing.